U.S. Food and Drug Administration | Module 6 – Applying MIDD Strategies to Decision-Making @US_FDA | Uploaded 2 months ago | Updated 1 hour ago
Dr. Mark R. Gasronguay, Founder and CEO of the Metrum Research Group, discusses how to use simulation from a mathematical model to evaluate scenarios and explore different decision paths. He wraps up with some assumption checking and additional examples of MIDD in practice.
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
Dr. Mark R. Gasronguay, Founder and CEO of the Metrum Research Group, discusses how to use simulation from a mathematical model to evaluate scenarios and explore different decision paths. He wraps up with some assumption checking and additional examples of MIDD in practice.
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
